DK3541387T3 - Dosis og regime for hdm2-p53-interaktionsinhibitorer - Google Patents
Dosis og regime for hdm2-p53-interaktionsinhibitorer Download PDFInfo
- Publication number
- DK3541387T3 DK3541387T3 DK17804304.8T DK17804304T DK3541387T3 DK 3541387 T3 DK3541387 T3 DK 3541387T3 DK 17804304 T DK17804304 T DK 17804304T DK 3541387 T3 DK3541387 T3 DK 3541387T3
- Authority
- DK
- Denmark
- Prior art keywords
- hdm2
- regime
- dosage
- interaction inhibitors
- inhibitors
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 230000003993 interaction Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662422144P | 2016-11-15 | 2016-11-15 | |
US201762479391P | 2017-03-31 | 2017-03-31 | |
PCT/IB2017/057097 WO2018092020A1 (en) | 2016-11-15 | 2017-11-14 | Dose and regimen for hdm2-p53 interaction inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
DK3541387T3 true DK3541387T3 (da) | 2021-07-19 |
Family
ID=60452703
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK17804304.8T DK3541387T3 (da) | 2016-11-15 | 2017-11-14 | Dosis og regime for hdm2-p53-interaktionsinhibitorer |
Country Status (18)
Country | Link |
---|---|
US (1) | US10966978B2 (da) |
EP (1) | EP3541387B1 (da) |
JP (1) | JP6890659B2 (da) |
KR (1) | KR102325778B1 (da) |
CN (2) | CN115252786A (da) |
AU (1) | AU2017362040C1 (da) |
CA (1) | CA3043004A1 (da) |
DK (1) | DK3541387T3 (da) |
ES (1) | ES2880149T3 (da) |
HU (1) | HUE055509T2 (da) |
IL (1) | IL266171B (da) |
MX (1) | MX2019005623A (da) |
PL (1) | PL3541387T3 (da) |
PT (1) | PT3541387T (da) |
RU (1) | RU2762573C2 (da) |
SI (1) | SI3541387T1 (da) |
TW (1) | TWI757367B (da) |
WO (1) | WO2018092020A1 (da) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW201613576A (en) | 2014-06-26 | 2016-04-16 | Novartis Ag | Intermittent dosing of MDM2 inhibitor |
SI3541387T1 (sl) | 2016-11-15 | 2021-08-31 | Novartis Ag | Odmerek in režim za zaviralce interakcije HDM2-P53 |
WO2018178925A1 (en) * | 2017-03-31 | 2018-10-04 | Novartis Ag | Dose and regimen for an hdm2-p53 interaction inhibitor in hematological tumors |
US11091522B2 (en) | 2018-07-23 | 2021-08-17 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and uses thereof |
CN110963958A (zh) * | 2018-09-30 | 2020-04-07 | 上海长森药业有限公司 | 一种mdm2抑制剂,及其制备方法、药物组合物和应用 |
JP2022505884A (ja) * | 2018-10-30 | 2022-01-14 | デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド | p53WT腫瘍の処置の方法 |
WO2020128898A1 (en) * | 2018-12-20 | 2020-06-25 | Novartis Ag | Pharmaceutical combinations |
WO2021066443A1 (ko) * | 2019-09-30 | 2021-04-08 | 한미약품 주식회사 | Flt3 저해제 및 mdm2 저해제를 포함하는 급성 골수성 백혈병 치료용 약학적 조성물 |
WO2021211819A1 (en) * | 2020-04-16 | 2021-10-21 | Albert Einstein College Of Medicine | Inhibition of bax-mediated cell death by eltrombopag |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6548531B2 (en) | 2001-02-09 | 2003-04-15 | Hoffmann-La Roche Inc. | Method for cancer therapy |
US20030139373A1 (en) | 2001-11-20 | 2003-07-24 | Breimer Lars Holger | Method for cancer therapy |
CU24130B1 (es) | 2009-12-22 | 2015-09-29 | Novartis Ag | Isoquinolinonas y quinazolinonas sustituidas |
US8440693B2 (en) * | 2009-12-22 | 2013-05-14 | Novartis Ag | Substituted isoquinolinones and quinazolinones |
WO2012065022A2 (en) | 2010-11-12 | 2012-05-18 | The Regents Of The University Of Michigan | Spiro-oxindole mdm2 antagonists |
WO2013096150A1 (en) | 2011-12-21 | 2013-06-27 | Merck Sharp & Dohme Corp. | Substituted piperidines as hdm2 inhibitors |
US8815926B2 (en) * | 2012-01-26 | 2014-08-26 | Novartis Ag | Substituted pyrrolo[3,4-D]imidazoles for the treatment of MDM2/4 mediated diseases |
US20130245089A1 (en) * | 2012-03-19 | 2013-09-19 | Hoffmann-La Roche Inc. | Method for administration |
CA2926307C (en) | 2013-12-05 | 2021-11-16 | F. Hoffmann-La Roche Ag | Novel combination treatment for acute myeloid leukemia (aml) |
TW201613576A (en) * | 2014-06-26 | 2016-04-16 | Novartis Ag | Intermittent dosing of MDM2 inhibitor |
US20170340733A1 (en) | 2014-12-19 | 2017-11-30 | Novartis Ag | Combination therapies |
CA2981753A1 (en) | 2015-02-06 | 2016-08-11 | Unity Biotechnology, Inc. | Compounds and uses in treatment of senescence-associated conditions |
AU2016308704B2 (en) | 2015-08-14 | 2019-06-20 | Novartis Ag | MDM2 inhibitors for treating uveal melanoma |
SI3541387T1 (sl) | 2016-11-15 | 2021-08-31 | Novartis Ag | Odmerek in režim za zaviralce interakcije HDM2-P53 |
WO2018178925A1 (en) | 2017-03-31 | 2018-10-04 | Novartis Ag | Dose and regimen for an hdm2-p53 interaction inhibitor in hematological tumors |
-
2017
- 2017-11-14 SI SI201730843T patent/SI3541387T1/sl unknown
- 2017-11-14 AU AU2017362040A patent/AU2017362040C1/en active Active
- 2017-11-14 EP EP17804304.8A patent/EP3541387B1/en active Active
- 2017-11-14 KR KR1020197016797A patent/KR102325778B1/ko active IP Right Grant
- 2017-11-14 CA CA3043004A patent/CA3043004A1/en active Pending
- 2017-11-14 RU RU2019118261A patent/RU2762573C2/ru active
- 2017-11-14 PT PT178043048T patent/PT3541387T/pt unknown
- 2017-11-14 CN CN202210905351.1A patent/CN115252786A/zh active Pending
- 2017-11-14 JP JP2019525886A patent/JP6890659B2/ja active Active
- 2017-11-14 WO PCT/IB2017/057097 patent/WO2018092020A1/en unknown
- 2017-11-14 ES ES17804304T patent/ES2880149T3/es active Active
- 2017-11-14 CN CN201780070276.9A patent/CN109982702A/zh active Pending
- 2017-11-14 MX MX2019005623A patent/MX2019005623A/es unknown
- 2017-11-14 DK DK17804304.8T patent/DK3541387T3/da active
- 2017-11-14 HU HUE17804304A patent/HUE055509T2/hu unknown
- 2017-11-14 US US16/461,005 patent/US10966978B2/en active Active
- 2017-11-14 PL PL17804304T patent/PL3541387T3/pl unknown
- 2017-11-15 TW TW106139404A patent/TWI757367B/zh active
-
2019
- 2019-04-22 IL IL266171A patent/IL266171B/en unknown
Also Published As
Publication number | Publication date |
---|---|
CN115252786A (zh) | 2022-11-01 |
AU2017362040A1 (en) | 2019-05-02 |
ES2880149T3 (es) | 2021-11-23 |
RU2762573C2 (ru) | 2021-12-21 |
IL266171A (en) | 2019-06-30 |
SI3541387T1 (sl) | 2021-08-31 |
PL3541387T3 (pl) | 2021-10-25 |
RU2019118261A3 (da) | 2021-03-18 |
AU2017362040B2 (en) | 2020-04-30 |
PT3541387T (pt) | 2021-07-14 |
IL266171B (en) | 2021-12-01 |
MX2019005623A (es) | 2019-08-14 |
CN109982702A (zh) | 2019-07-05 |
US10966978B2 (en) | 2021-04-06 |
JP6890659B2 (ja) | 2021-06-18 |
US20190298719A1 (en) | 2019-10-03 |
KR20190084292A (ko) | 2019-07-16 |
CA3043004A1 (en) | 2018-05-24 |
AU2017362040C1 (en) | 2020-09-10 |
EP3541387A1 (en) | 2019-09-25 |
TW201822817A (zh) | 2018-07-01 |
HUE055509T2 (hu) | 2021-12-28 |
RU2019118261A (ru) | 2020-12-17 |
TWI757367B (zh) | 2022-03-11 |
KR102325778B1 (ko) | 2021-11-12 |
WO2018092020A1 (en) | 2018-05-24 |
JP2020500190A (ja) | 2020-01-09 |
EP3541387B1 (en) | 2021-04-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK3541387T3 (da) | Dosis og regime for hdm2-p53-interaktionsinhibitorer | |
DK3368069T3 (da) | Anvendelse af myostatininhibitorer og kombinationsterapier | |
DK3386484T3 (da) | Sammensætninger og fremgangsmåder til afgivelse af terapeutiske midler | |
DK3565550T3 (da) | Farmaceutiske sammensætninger omfattende meloxicam og rizatriptan | |
DK3317284T3 (da) | Benzoxazepin-oxazolidinonforbindelser og fremgangsmåder til anvendelse | |
DK3464282T3 (da) | Heteroarylsubstituerede pyridiner og fremgangsmåder til anvendelse | |
DK3350157T3 (da) | Forbindelser og sammensætninger til intracellulær afgivelse af terapeutiske midler | |
DK3521289T3 (da) | Mnk-inhibitorer og fremgangsmåder forbundet dermed | |
DK3548033T3 (da) | Forbindelser og deres fremgangsmåde til anvendelse | |
DK3389658T3 (da) | Glycosidasehæmmere og anvendelser deraf | |
DK3295951T3 (da) | Anti-pvrig-antistoffer og fremgangsmåder for anvendelse | |
DK3234133T3 (da) | Crispr-baserede sammensætninger og fremgangsmåder til anvendelse | |
DK3452485T3 (da) | Arginasehæmmere og deres terapeutiske anvendelser | |
DK3177608T3 (da) | Proteinkinase-C-hæmmere og fremgangsmåder til anvendelse deraf | |
DK3227310T3 (da) | Heterobifunktionelle inhibitorer af e-selektiner og cxcr4-kemokin-receptorer | |
DK3487505T3 (da) | Indgivelse og dosering af diaminophenothiaziner | |
DK3263565T3 (da) | Cyklisk aminderivat og farmaceutisk anvendelse deraf | |
DK3394065T3 (da) | Tetrahydropyranyl-amino-pyrrolopyrimidinon og fremgangsmåder til anvendelse deraf | |
DK3532459T3 (da) | Lsd1-hæmmere og medicinske anvendelser deraf | |
DK3089971T3 (da) | Forbindelser og fremgangsmåder til anvendelse | |
DK3543240T3 (da) | URAT1-inhibitor og anvendelse deraf | |
DK3278803T3 (da) | Fast farmaceutisk doseringsform af PARP-inhibitor, og anvendelse af fast farmaceutisk doseringsform af PARP-inhibitor | |
DK3380525T3 (da) | Farmaceutiske formuleringer og fremgangsmåder til anvendelse deraf | |
DK3107902T3 (da) | Forbindelser og fremgangsmåder til at hæmme fascin | |
DK3621694T3 (da) | Lrrc33-inhibitorer og anvendelse heraf |